Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04394624
Title Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04) (CARMEN-LC04)
Acronym CARMEN-LC04
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sanofi
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ESP | CZE | BGR


No variant requirements are available.